Against of backdrop of unsuccessful new drug discovery, patent expiry and a particularly tough global economic economy, the pharmaceutical industry model has had to change and over the last 10 years in the quest to remain profitable.
Pharmaceutical manufacturers have increasingly turned to the resources and experience of external companies such as contract manufacturing organisations (CMOs) to manufacture finished products in their portfolios and new drugs for clinical trials.
However this model is being stretched even further as companies are now seeking strategic partnerships with their CMOs, co–developing products and sharing both risk and reward.
In this report we examine external and internal pressures on pharmaceutical companies and assess how these have impacted pharmaceutical manufacturing, the contract manufacturing landscape and the growth and dynamics of contract manufacturing in emerging markets, such as China and Russia.
|
|
Have Your Say Rate this feature and give us your feedback in the comments section below |